Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.

BACKGROUND: The mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in adults ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented. METHODS: This phase 2/3 trial randomly assigned adults (≥60 years) to mRNA-1345 50-µg encoding prefusion F (preF) glycoprotein (n = 17,793) vaccine or placebo (n = 17,748). RSV-A and RSV-B neutralizing antibody (nAb) and preF binding antibody (bAb) levels at baseline and day 29 post-vaccination were assessed in a per-protocol immunogenicity subset ([PPIS]; mRNA-1345, n = 1515; placebo, n = 333). RESULTS: Day 29 nAb geometric mean titers (GMTs) increased 8.4-fold against RSV-A and 5.1-fold against RSV-B from baseline. Seroresponses (4-fold rise from baseline) in the mRNA-1345 groups were 74.2% and 56.5% for RSV-A and RSV-B, respectively. Baseline GMTs were lower among participants who met the seroresponse criteria than those who did not. mRNA-1345 induced preF bAbs at day 29, with a pattern similar to nAbs. Day 29 antibody responses across demographic and risk subgroups were generally consistent with the overall PPIS. CONCLUSION: mRNA-1345 enhanced RSV-A and RSV-B nAbs and preF bAbs in adults (≥60 years) across various subgroups, including those at risk for severe disease, consistent with its demonstrated efficacy in the prevention of RSV disease.

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.

The objective of this study was to evaluate the safety and efficacy of bermekimab, an IL-1α inhibitor, in the treatment of hidradenitis suppurativa (HS). This study was a phase II, multicenter, open-label study of two dose cohorts of bermekimab in patients with moderate-to-severe HS who are naïve to or have failed prior anti-TNF therapy. Patients with HS (n = 42) were divided into groups A and B based on whether or not they had previously failed an anti-TNF therapy. In group A (n = 24), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who had previously failed anti-TNF therapy; in group B (n = 18), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who were anti-TNF naïve. Bermekimab, previously found to be effective in treating HS, was evaluated using a subcutaneous formulation in patients with HS naïve to or having failed anti-TNF therapy. There were no bermekimab-related adverse events with the exception of injection site reactions. Bermekimab was effective despite treatment history, with 61% and 63% of patients naïve to and having failed anti-TNF therapy, respectively, achieving HS clinical response after 12 weeks of treatment. A significant reduction in abscesses and inflammatory nodules of 60% (P < 0.004) and 46% (P < 0.001) was seen in anti-TNF naïve and anti-TNF failure groups, respectively. Clinically and statistically significant reduction was seen in patients experiencing pain, with the Visual Analogue Scale pain score reducing by 64% (P < 0.001) and 54% (P < 0.001) in the anti-TNF naïve and anti-TNF failure groups, respectively. IL-1α is emerging as an important clinical target for skin disease, and bermekimab may represent a new therapeutic option for treating moderate-to-severe HS.

Fitorremediación de aguas contaminadas con componentes de amalgama de la preclínica de odontología de la Universidad Antonio Nariño, Ibagué (Colombia) / Phytoremediation of contaminated water with amalgam components of the preclinical dentistry of the Universidad Antonio Nariño, Ibagué Colombia

Objetivo: remover componentes de amalgama de aguas contaminadas mediante fitorremediación. Métodos: se llevó a cabo un estudio descriptivo retrospectivo, en que fueron recolectados 12 litros de aguas de remoción de obturaciones de amalgama en 144 dientes artificiales en la preclínica de odontología. Se analizó agua sin fitorremediar (control), y se mantuvieron ocho litros para fitorremediación en el Laboratorio de Ciencias Básicas y un análisis semanal con dos especies de plantas acuáticas: Eichhornia crassipes y Pistia stratiotes. Mediante espectrofotometría de absorción atómica, se determinó la concentración de metales pesados en miligramos por litro. El análisis se llevó a cabo mediante estadística descriptiva, comparación con prueba t y ANOVA de una vía con el complemento de Excel XLSTAT. Resultados: tras el proceso, el porcentaje estimado de remoción de componentes de amalgama fue superior al 50%. No hubo diferencias estadísticamente significativas entre los tratamientos (α= 0.05; g l= 11; p= 0,4269). Conclusiones: se logró la remoción parcial de componentes de amalgama de aguas contaminadas a través del proceso de fitorremediación.

Objective: remove amalgam components from contaminated water by phytoremediation. Methods: a retrospective descriptive study was carried out, in which 12 liters of amalgam filling removal water were collected in 144 artificial teeth in the preclinical dentistry. Water was analyzed without phytoremediation (control), and eight liters were maintained for phytoremediation in the Laboratory of Basic Sciences and a weekly analysis with two species of aquatic plants: Eichhornia crassipes and Pistia stratiotes. The concentration of heavy metals in milligrams per liter was determined by atomic absorption spectrophotometry. The analysis was carried out using descriptive statistics, comparison with t-test and one-way ANOVA with the Excel XLSTAT add-in. Results: after the process, the estimated removal percentage of amalgam components was greater than 50%. There were no statistically significant differences between treatments (α = 0.05; g l = 11; p = 0.4269). Conclusions: the partial removal of amalgam components from contaminated water was achieved through the phytoremediation process.

Tratamiento quirúrgico de la incontinencia urinaria de esfuerzo: III: operación de Burch / Surgical treatment of stress urinary incontinence: III: Burch's operation

En un periodo de 33 meses (enero de 1984 a octubre de 1986) en el Hospital "Luis Castelazo Ayala" del IMSS., se realizaron 35 operaciones de cistouretropexia retropúbica con el procedimiento de Burch, en pacientes seleccionadas conforme a un protocolo establecido. La patología concomitante más frecuentemente observada, por la cual en un segundo tiempo se indicó la operación de Burch, fue la uterina, siguiéndole en orden decreciente la incontinencia urinaria recidivante, control definitivo de la fertilidad y patología anexial. Se observaron complicaciones transoperatorias en 14.3% de los casos; siendo la de mayor relevancia una lesión vesical. Se obtuvo un porcentaje de curaciones de 83% con seis fracasos, cuatro de los cuales correspondieron a pacientes operadas en los primeros cuatro meses